Financial Data and Key Metrics Changes - The company reported Q1 2025 net sales of $88 million, representing a 4% year-over-year growth, despite a tough comparison from Q1 2024 which had 18% growth [5][19] - Adjusted gross profit margin was 84% for the quarter, while GAAP gross margin was 81%, down from 85% in the prior year [21][24] - Adjusted EBITDA was $17 million, or 20% of net sales, compared to $19 million, or 22% of net sales in the prior year [24] - The company ended the quarter with $106 million in cash, an increase of $2 million during the quarter [8][25] Business Line Data and Key Metrics Changes - Surgical sales grew by 16% to $32 million, driven by strong performance from AmnioFect and HelioGen [20] - Wound sales declined by 2% to $56 million, facing challenges due to Medicare reimbursement disruptions [20][12] - The Amneal branded products grew by 22% in Q1, while HelioGen showed sequential growth from a low base [11] Market Data and Key Metrics Changes - The company noted that approximately 25% of its overall business has ASP exposure, which complicates pricing strategies in the current reimbursement environment [15][47] - The ongoing disruption in the private office and associated care settings due to Medicare reimbursement issues has impacted sales, particularly in the wound care segment [6][12] Company Strategy and Development Direction - The company aims to innovate and diversify its product portfolio, focusing on unique product configurations to meet customer needs [10] - Strategic priorities include expanding the surgical market footprint and enhancing customer relationships through programs like Mimetics Connect [16][18] - The company is actively pursuing opportunities for organic and inorganic growth, including potential acquisitions [62] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment over the delay in Medicare reimbursement reforms but remains committed to advocating for necessary changes [27][28] - The company reiterated its full-year revenue growth outlook to be at least in the high single digits, with expectations for higher growth rates in the latter half of the year [31] - Long-term prospects remain positive, with expectations of resetting top-line growth to low double digits post-reform [31] Other Important Information - The company has contingency plans in place to adapt to the current reimbursement environment and is exploring third-party manufactured products to retain customers [13][15] - Management emphasized the importance of generating clinical evidence to support product use in surgical applications [16] Q&A Session Summary Question: Adjusted gross profit margin expectations - Management confirmed that the adjusted gross profit margin of 84% in Q1 was related to product mix and expected some pressure from ASPs throughout the year [35] Question: Progress on Equifax in Japan - Management indicated that growth in Japan is on track but remains relatively small in overall contribution [37] Question: Overall reimbursement landscape and confidence in future changes - Management expressed frustration over the lack of changes in the reimbursement landscape but remains hopeful for future reforms [42][44] Question: Shifting private office volumes to new products - Management stated that the shift to higher-priced products is a necessary step to protect business but cautioned against expecting significant volume conversion [50][52] Question: Efforts to prepare for a better market environment - Management highlighted the importance of executing their plan, expanding product offerings, and investing in commercial strength and clinical research [60][62] Question: Changes in purchasing patterns due to LCD delays - Management suggested that there may be shifts in purchasing patterns as higher-priced products become more prevalent, but the overall impact remains uncertain [70][74]

Financial Data and Key Metrics Changes - The company reported Q1 2025 net sales of $88 million, representing a 4% year-over-year growth despite a tough comparison from Q1 2024, which had an 18% growth [8][19] - Adjusted gross profit margin was 84% for the quarter, while GAAP gross margin was 81%, down from 85% in the prior year [21][25] - Adjusted EBITDA was $17 million, or 20% of net sales, compared to $19 million, or 22% of net sales in the prior year [25][27] - The company ended the quarter with $106 million in cash, an increase of $2 million during the quarter [8][26] Business Line Data and Key Metrics Changes - Surgical sales grew by 16% to $32 million, driven by strong performance from AmnioFect and HelioGen [20] - Wound sales declined by 2% to $56 million, facing challenges due to Medicare reimbursement disruptions [20][12] - The Amneal branded products, particularly Amnealophenic, grew by 22% in Q1 [11] Market Data and Key Metrics Changes - The company faced ongoing disruptions in the private office and associated care settings due to the current Medicare reimbursement system [6][12] - Approximately 25% of the company's overall business has ASP exposure, making it manageable despite the challenges [46] Company Strategy and Development Direction - The company aims to innovate and diversify its product portfolio, focusing on developing unique product configurations to meet customer needs [10] - Strategic priorities include expanding the surgical market footprint, enhancing customer intimacy, and developing clinical evidence to support product use [15][18] - The company is actively pursuing opportunities for organic and inorganic growth to support business diversification [26] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment over the delay in Medicare reimbursement reforms but remains committed to advocating for necessary changes [29][32] - The company reiterated its full-year revenue growth outlook to be at least in the high single digits, with expectations for higher growth rates in the latter half of the year [31] - Long-term prospects remain positive, with expectations to reset top-line growth to low double digits post-reform [31][32] Other Important Information - The company has contingency plans in place to adapt to the current environment and maintain competitiveness [7][14] - Management emphasized the importance of generating cash flow, even during high cash burn periods [27] Q&A Session Summary Question: Adjusted gross profit margin expectations - Management acknowledged that the adjusted gross profit margin was 84.1% in Q1 and attributed future changes to product mix [35] Question: Progress on Equifax in Japan - Management indicated that growth in Japan is on track but remains relatively small in overall contribution [36] Question: Overall reimbursement landscape and confidence in future changes - Management expressed frustration over the lack of changes in the reimbursement landscape but remains hopeful for future reforms [40][46] Question: Shifting private office volumes to new products - Management stated that shifting volumes to higher-priced products is a necessary step to protect business but cautioned against expecting significant windfalls [48][52] Question: Surgical growth driven by HelioGen - Management noted that surgical growth was driven by better execution across the portfolio, with no specific new data driving volumes [53][55] Question: Preparing for a better market environment - Management highlighted ongoing efforts to expand product offerings and invest in commercial strength to prepare for future growth [58][61]

Core Insights - MiMedx Group, Inc. reported net sales of $88 million for the first quarter of 2025, reflecting a 4% year-over-year growth, primarily driven by a 16% increase in Surgical products [1][3][30] - The company reaffirmed its expectations for net sales growth in 2025 to be at least in the high single digits as a percentage compared to 2024, with an Adjusted EBITDA margin expected to be above 20% for the full year [8][22] Financial Performance - First quarter GAAP net income was $7 million, or $0.05 per share, compared to $9 million, or $0.06 per share, in the same period last year [1][6][28] - Adjusted EBITDA for the first quarter was $17 million, representing 20% of net sales, down from 22% in the prior year [1][22] - Gross profit was $72 million, with a gross margin of 81%, down from 85% year-over-year, attributed to product variances and mix [4][30] Operating Expenses - Selling, general and administrative (SG&A) expenses increased to $60 million from $55 million year-over-year, driven by higher commissions, salary increases, and legal costs [5][30] - Research and development (R&D) expenses remained flat at $3 million, focusing on ongoing product development and clinical trials [6][30] Cash Position - As of March 31, 2025, the company had $106 million in cash and cash equivalents, a slight increase from $104 million at the end of 2024 [7][30] - The net cash position, after accounting for debt, was $88 million, reflecting a sequential increase of $2 million [7] Product Performance - Surgical products experienced double-digit growth, while Wound products saw a 2% decline compared to the previous year [2][3] - The company introduced CELERA™ to its portfolio as a strategic response to market challenges [2] Future Outlook - MiMedx aims for long-term annual net sales growth in the low double digits, with a continued focus on expanding the use cases for its proprietary technology [8][2] - The company plans to introduce additional products throughout the year, both organically and through acquisitions [2]

Part I - FINANCIAL INFORMATION [Item 1. Financial Statements (Unaudited)](index=5&type=section&id=Item%201.%20Financial%20Statements%20(Unaudited)) This section presents the unaudited condensed consolidated financial statements for Q1 2025, including balance sheets, income statements, equity statements, cash flows, and explanatory notes [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of March 31, 2025, total assets increased to $270.4 million from $263.9 million, driven by higher cash and accounts receivable, while total liabilities decreased to $67.6 million, leading to an increase in total stockholders' equity to $202.8 million Condensed Consolidated Balance Sheets (in thousands) | | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Total current assets** | $200,112 | $191,886 | | **Total assets** | $270,420 | $263,915 | | **Total current liabilities** | $42,619 | $45,595 | | **Total liabilities** | $67,644 | $70,808 | | **Total stockholders' equity** | $202,776 | $193,107 | [Condensed Consolidated Statements of Operations](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) For Q1 2025, net sales increased 4.1% to $88.2 million, but net income decreased to $7.0 million from $9.3 million year-over-year due to higher cost of sales and operating expenses, resulting in diluted net income per share of $0.05 Statements of Operations Highlights (in thousands, except per share data) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net sales | $88,205 | $84,709 | | Gross profit | $71,647 | $71,722 | | Operating income | $8,251 | $13,198 | | Net income | $7,023 | $9,261 | | Diluted net income per common share | $0.05 | $0.06 | [Condensed Consolidated Statements of Stockholders' Equity](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Stockholders%20Equity) Total stockholders' equity increased to $202.8 million as of March 31, 2025, primarily driven by net income and share-based compensation - Stockholders' equity grew to **$202.8 million** as of March 31, 2025, up from **$193.1 million** at the end of 2024, mainly due to net income and share-based compensation[19](index=19&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) In Q1 2025, net cash provided by operating activities was $5.3 million, while investing and financing activities used $0.4 million and $2.9 million respectively, leading to a net increase in cash of $2.0 million and a cash balance of $106.4 million Cash Flow Summary (in thousands) | Cash Flow Activity | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net cash provided by operating activities | $5,299 | $5,978 | | Net cash used in investing activities | ($406) | ($6,024) | | Net cash used in financing activities | ($2,878) | ($33,467) | | **Net change in cash** | **$2,015** | **($33,513)** | | **Cash and cash equivalents, end of period** | **$106,431** | **$48,487** | [Notes to the Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20the%20Condensed%20Consolidated%20Financial%20Statements) The notes provide detailed information on the company's wound care and surgical business, accounting policies, and financial statement breakdowns, including revenue by product line, credit agreement details, and ongoing litigation with the FDA regarding AXIOFILL - The company is engaged in litigation with the FDA over the regulatory classification of its AXIOFILL product. MIMEDX filed a suit in March 2024 challenging the FDA's determination, and oral arguments on summary judgment motions were held in March 2025[54](index=54&type=chunk)[55](index=55&type=chunk) Net Sales by Product Line (in thousands) | Product Line | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Wound | $56,073 | $57,049 | | Surgical | $32,132 | $27,660 | | **Total** | **$88,205** | **$84,709** | - In January 2024, the company entered into a new credit agreement with Citizens Bank, including a **$30.0 million** Revolving Credit Facility and a **$20.0 million** Term Loan Facility, to refinance a previous loan[41](index=41&type=chunk) - The company has a single operating segment, and its Chief Executive Officer is identified as the Chief Operating Decision Maker (CODM)[58](index=58&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=17&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the Q1 2025 financial results, highlighting a 4% year-over-year net sales growth to $88 million, driven by a 16.2% increase in the Surgical product line, which offset a 1.7% decline in the Wound segment, with GAAP net income at $7 million and sufficient liquidity for the next twelve months Q1 2025 Financial Highlights | Metric | Value | Change vs. Prior Year Period | | :--- | :--- | :--- | | Net Sales ($ million) | $88 | +4% | | Wound Net Sales ($ million) | $56 | -1.7% | | Surgical Net Sales ($ million) | $32 | +16.2% | | GAAP Net Income ($ million) | $7 | - | | GAAP Net Income Margin (%) | 8% | - | | Cash Balance ($ million) | $106 | +$58 | [Results of Operations](index=20&type=section&id=Results%20of%20Operations) Net sales increased 4.1% to $88.2 million in Q1 2025, driven by 16.2% growth in Surgical products offsetting a 1.7% decline in Wound products, while gross margin decreased to 81.2% and operating expenses rose due to higher sales commissions, legal costs, and R&D investments - Surgical product sales grew **16.2%** to **$32.1 million**, driven by AMNIOFIX, AMNIOEFFECT, and HELIOGEN products[70](index=70&type=chunk) - Wound product sales decreased **1.7%** to **$56.1 million**, attributed to competitive challenges in the private office setting and sales team turnover, partially offset by the addition of CELERA[69](index=69&type=chunk) - Gross profit margin declined to **81.2%** from **84.7%** in the prior year, primarily due to production variances, product mix, and amortization of acquired intangible assets[71](index=71&type=chunk) - SG&A expenses increased by **$4.8 million (8.8%)** year-over-year, driven by higher sales commissions and incremental legal and regulatory dispute costs[72](index=72&type=chunk) [Liquidity and Capital Resources](index=21&type=section&id=Liquidity%20and%20Capital%20Resources) The company maintains a strong liquidity position with cash and cash equivalents at $106.4 million and a current ratio of 4.7, supported by $5.3 million in operating cash flow and available credit facilities, affirming sufficient capital for the next twelve months - As of March 31, 2025, the company had **$106.4 million** in cash and cash equivalents and a current ratio of **4.7**[81](index=81&type=chunk) - Net cash provided by operating activities decreased to **$5.3 million** in Q1 2025 from **$6.8 million** in Q1 2024, due to lower collections and greater expenses[77](index=77&type=chunk) - The company entered into a new Citizens Credit Agreement in January 2024, consisting of a **$20.0 million** Term Loan Facility and a **$30.0 million** Revolving Credit Facility (which was undrawn as of March 31, 2025)[83](index=83&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=22&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risk exposure is interest rate risk from its variable-rate Term Loan Facility, which is tied to the 1-month term SOFR, and it does not utilize hedging instruments to mitigate this risk - As of March 31, 2025, the interest rate on the Term Loan Facility was **6.7%**. A hypothetical **100 basis point (1%)** change in the SOFR rate would impact annualized interest expense by approximately **$0.2 million**[89](index=89&type=chunk) [Item 4. Controls and Procedures](index=22&type=section&id=Item%204.%20Controls%20and%20Procedures) Management, including the CEO and CFO, concluded that the company's disclosure controls and procedures were effective as of March 31, 2025, with no material changes to internal control over financial reporting during the quarter - Management concluded that disclosure controls and procedures were effective at a reasonable assurance level as of the end of the reporting period[90](index=90&type=chunk) - No changes occurred in internal control over financial reporting during the quarter that have materially affected, or are reasonably likely to materially affect, these controls[91](index=91&type=chunk) Part II - OTHER INFORMATION [Item 1. Legal Proceedings](index=23&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in various claims and lawsuits arising in the ordinary course of business, with their ultimate outcomes currently uncertain, and specific details on matters like the AXIOFILL litigation are provided in the financial statement notes - The company is involved in numerous claims and lawsuits arising from its ordinary business activities, with outcomes that are currently uncertain[93](index=93&type=chunk) [Item 1A. Risk Factors](index=24&type=section&id=Item%201A.%20Risk%20Factors) No material changes to the company's previously disclosed risk factors were reported for the period - No material changes to the Company's risk factors were reported for the period[94](index=94&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=24&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered sales of equity securities but repurchased 301,301 shares at an average price of $8.16 per share during the quarter to satisfy tax withholding obligations related to employee restricted stock unit vesting Company's Equity Securities Purchases (Q1 2025) | Period | Total Shares Purchased | Average Price Paid per Share | | :--- | :--- | :--- | | January 2025 | — | $ — | | February 2025 | 186,242 | $ 8.30 | | March 2025 | 115,059 | $ 7.93 | | **Total** | **301,301** | **$ 8.16** | - The share purchases represent net settlement of shares upon vesting of employee restricted stock units to satisfy tax withholding obligations[96](index=96&type=chunk) [Item 5. Other Information](index=24&type=section&id=Item%205.%20Other%20Information) During the first quarter of 2025, no director or officer of the company adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement - No director or officer adopted or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading arrangement during the three months ended March 31, 2025[99](index=99&type=chunk) [Item 6. Exhibits](index=25&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Form 10-Q, including CEO and CFO certifications required by the Sarbanes-Oxley Act and XBRL data files for financial reporting - Filed exhibits include CEO and CFO certifications pursuant to Sections 302 and 906 of the Sarbanes-Oxley Act, along with XBRL instance and schema documents[100](index=100&type=chunk)

[First Quarter 2025 Operating and Financial Results](index=1&type=section&id=First%20Quarter%202025%20Operating%20and%20Financial%20Results) This section details MIMEDX's Q1 2025 financial performance, strategic highlights, and future outlook [Q1 2025 Highlights & CEO Commentary](index=1&type=section&id=Q1%202025%20Highlights%20%26%20CEO%20Commentary) MIMEDX reported solid Q1 2025 results with 4% net sales growth and 20% Adjusted EBITDA margin, driven by Surgical products and new product introductions Q1 2025 Key Financial Metrics | Metric | Q1 2025 | YoY Change | | :--- | :--- | :--- | | Net Sales | $88 million | +4% | | GAAP Net Income | $7 million | - | | GAAP EPS | $0.05 | - | | Adjusted EBITDA | $17 million | - | | Adjusted EBITDA Margin | 20% | - | - Surgical products recorded **double-digit growth**, unlocking sizable market opportunities through a growing body of clinical evidence[2](index=2&type=chunk) - The company plans to mitigate the impact of delayed LCDs by introducing new products, including the recently added CELERA™, and pursuing both organic and inorganic pipeline additions[2](index=2&type=chunk) [Detailed Financial Performance](index=1&type=section&id=First%20Quarter%202025%20Results%20Discussion) Q1 2025 net sales increased 4% to $88 million, driven by Surgical products, despite a gross margin decline and higher operating expenses Q1 2025 vs Q1 2024 Performance | Metric | Q1 2025 ($M) | Q1 2024 ($M) | | :--- | :--- | :--- | | Net Sales | $88.0M | $85.0M | | Gross Profit | $72.0M | $72.0M | | Gross Margin | 81% | 85% | | SG&A Expenses | $60.0M | $55.0M | | Net Income | $7.0M | $9.0M | - The **4% net sales growth** was primarily driven by a **16% increase** in Surgical products, while Wound products saw a **2% decline**[3](index=3&type=chunk) - The increase in SG&A expenses was attributed to higher sales commissions, salary and benefit costs, and incremental legal and regulatory dispute expenses[6](index=6&type=chunk) - Cash and cash equivalents increased to **$106 million** as of March 31, 2025, from **$104 million** at the end of 2024[8](index=8&type=chunk) [Financial Outlook](index=2&type=section&id=Financial%20Outlook) MIMEDX reaffirms 2025 guidance for high single-digit net sales growth and over 20% Adjusted EBITDA margin, targeting long-term low double-digit growth - **2025 Outlook:** Net sales growth is expected to be at least in the **high single-digits**, with an Adjusted EBITDA margin **above 20%**[9](index=9&type=chunk) - **Longer-Term Outlook:** The company targets annual net sales growth in the **low double-digits** and an Adjusted EBITDA margin **exceeding 20%**[9](index=9&type=chunk) [Unaudited Financial Statements](index=4&type=section&id=Selected%20Unaudited%20Financial%20Information) This section presents the company's condensed consolidated balance sheets, statements of operations, and cash flows for Q1 2025 [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) The balance sheet as of March 31, 2025, shows total assets of $270.4 million and total liabilities of $67.6 million, reflecting stronger equity Balance Sheet Highlights (in thousands) | Account | March 31, 2025 (in thousands) | December 31, 2024 (in thousands) | | :--- | :--- | :--- | | Cash and cash equivalents | $106,431 | $104,416 | | Total current assets | $200,112 | $191,886 | | Total assets | $270,420 | $263,915 | | Total liabilities | $67,644 | $70,808 | | Total stockholders' equity | $202,776 | $193,107 | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Q1 2025 net sales increased 4.1% to $88.2 million, but higher operating expenses led to a decrease in net income to $7.0 million Statement of Operations Highlights (in thousands, except per share data) | Account | Q1 2025 (in thousands) | Q1 2024 (in thousands) | | :--- | :--- | :--- | | Net sales | $88,205 | $84,709 | | Gross profit | $71,647 | $71,722 | | Operating income | $8,251 | $13,198 | | Net income | $7,023 | $9,261 | | Diluted net income per common share | $0.05 | $0.06 | [Condensed Consolidated Statements of Cash Flows](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash from operating activities was $5.3 million in Q1 2025, contributing to a $2.0 million net increase in cash for the quarter Cash Flow Summary (in thousands) | Activity | Q1 2025 (in thousands) | Q1 2024 (in thousands) | | :--- | :--- | :--- | | Net cash from operating activities | $5,299 | $5,978 | | Net cash used in investing activities | ($406) | ($6,024) | | Net cash used in financing activities | ($2,878) | ($33,467) | | **Net change in cash** | **$2,015** | **($33,513)** | [Reconciliation of Non-GAAP Measures](index=6&type=section&id=Reconciliation%20of%20Non-GAAP%20Measures) This section provides reconciliations for Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, Free Cash Flow, and net sales by product category [Adjusted EBITDA](index=7&type=section&id=Adjusted%20EBITDA) Q1 2025 Adjusted EBITDA was $17.2 million (19.5% margin), reflecting a decrease from Q1 2024 after non-GAAP adjustments Adjusted EBITDA Reconciliation (in thousands) | Metric | Q1 2025 (in thousands) | Q1 2024 (in thousands) | | :--- | :--- | :--- | | Net Income | $7,023 | $9,261 | | Non-GAAP Adjustments | $10,198 | $9,404 | | **Adjusted EBITDA** | **$17,221** | **$18,665** | | **Adjusted EBITDA margin** | **19.5%** | **22.0%** | [Adjusted Net Income and Adjusted EPS](index=7&type=section&id=Adjusted%20Net%20Income%20and%20Adjusted%20EPS) Q1 2025 Adjusted Net Income was $9.6 million and Adjusted EPS was $0.06, reflecting adjustments for non-recurring items Adjusted Net Income & EPS Reconciliation | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | GAAP Net Income | $7.0M | $9.3M | | **Adjusted Net Income** | **$9.6M** | **$10.0M** | | GAAP Diluted EPS | $0.05 | $0.06 | | **Adjusted EPS** | **$0.06** | **$0.07** | [Free Cash Flow](index=10&type=section&id=Free%20Cash%20Flow) Q1 2025 Free Cash Flow increased slightly to $4.9 million, representing cash generated beyond capital investments Free Cash Flow Reconciliation (in thousands) | Metric | Q1 2025 (in thousands) | Q1 2024 (in thousands) | | :--- | :--- | :--- | | Net cash flows provided by operating activities | $5,299 | $5,978 | | Capital expenditures | ($377) | ($1,144) | | **Free Cash Flow** | **$4,922** | **$4,834** | [Net Sales by Product Category](index=10&type=section&id=Net%20Sales%20by%20Product%20Category) Q1 2025 net sales of $88.2 million were driven by 16.2% growth in Surgical products, offsetting a 1.7% decline in Wound products Net Sales by Product Category (in thousands) | Category | Q1 2025 (in thousands) | Q1 2024 (in thousands) | YoY Change | | :--- | :--- | :--- | :--- | | Wound | $56,073 | $57,049 | -1.7% | | Surgical | $32,132 | $27,660 | +16.2% | | **Total Net Sales** | **$88,205** | **$84,709** | **+4.1%** |

MARIETTA, Ga., April 16, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today announced that it will report its operating and financial results for the first quarter ended March 31, 2025 after the market close on Wednesday, April 30, 2025. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. MIMEDX is a pioneer and leader focused on helping humans heal. With more than a dec ...

Core Insights - MiMedx Group, Inc. will participate in several industry conferences this quarter to showcase its Advanced Wound Care and Surgical Solutions [1][2] - The company aims to highlight its commitment to innovation and the scientific evidence supporting its products at these conferences [2] Conference Participation - MiMedx will be featured at the Diabetic Limb Salvage (DLS) Conference from April 10-12, 2025, in Washington, D.C., where it will host a sponsored lunch symposium [3] - The company will also participate in the Symposium on Advanced Wound Care (SAWC) Spring 2025 from April 30 to May 4, 2025, in Grapevine, TX, with another sponsored lunch symposium [3] - Additionally, MiMedx will present at Digestive Disease Week (DDW) 2025 from May 3-6, 2025, in San Diego, CA, focusing on the use of amniotic tissues in colorectal surgery [4] Company Overview - MiMedx is recognized as a leader in providing solutions for chronic and hard-to-heal wounds, with a vision to be the leading global provider of healing solutions through innovation [4] - The company has over a decade of experience in the wound care, burn, and surgical sectors of healthcare [4] Conference Details - The DLS Conference emphasizes a multidisciplinary approach to wound healing and limb salvage, featuring an international faculty and promoting evidence-based practices [5] - The SAWC serves as a forum for the entire wound care team to connect and improve patient outcomes through education and advanced clinical reviews [6] - DDW is the largest international gathering in gastroenterology and related fields, showcasing over 4,400 abstracts and hundreds of lectures on the latest advances [7]

Core Insights - MiMedx Group, Inc. will participate in several industry conferences this quarter to showcase its Advanced Wound Care and Surgical Solutions [1][2] - The company aims to highlight its commitment to innovation and the scientific evidence supporting its products at these conferences [2] Conference Participation - MiMedx will be featured at the Diabetic Limb Salvage (DLS) Conference from April 10-12, 2025, in Washington, D.C., where it will host a sponsored lunch symposium [3] - The company will also participate in the Symposium on Advanced Wound Care (SAWC) Spring 2025 from April 30 to May 4, 2025, in Grapevine, TX, with another sponsored lunch symposium [3] - Additionally, MiMedx will present at the Digestive Disease Week (DDW) from May 3-6, 2025, in San Diego, CA, focusing on the use of amniotic tissues in colorectal surgery [4] Company Overview - MiMedx is recognized as a leader in providing solutions for chronic and hard-to-heal wounds, with a vision to be the global provider of healing solutions through innovation [4] - The company has over a decade of experience in the wound care, burn, and surgical sectors of healthcare [4] Conference Details - The DLS Conference emphasizes a multidisciplinary approach to wound healing and limb salvage, featuring an international faculty and promoting evidence-based practices [5] - The SAWC serves as a forum for various healthcare professionals to connect and improve patient outcomes through education and advanced clinical reviews [6] - DDW is the largest international gathering in gastroenterology and related fields, showcasing significant research and advancements in GI medicine [7]

MARIETTA, Ga., Feb. 27, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that senior management will participate in the TD Cowen 45th Annual Health Care Conference. TD Cowen's 45th Annual Health Care Conference is taking place on March 3-5, 2025, at the Boston Marriott Copley Place in Boston, MA. The conference incorporates presentations, fireside chats and innovative panel discussions, moderated by members of the TD Cowen research team, that focus on va ...

MiMedx Group, Inc. (NASDAQ:MDXG) Q4 2024 Earnings Conference Call February 26, 2024 4:30 AM ET Company Participants Matt Notarianni - Head, Investor Relations Joseph Capper - Chief Executive Officer Doug Rice - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Group Ross Osborn - Cantor Fitzgerald Bradley Bowers - Mizuho Securities Brooks O'Neil - Lake Street Capital Markets Carl Byrnes - Northland Capital Markets Operator Good afternoon, and thank you for standing by. ...